Abatacept Orencia®
The SHIKARI® Abatacept portfolio separates quantitative free-drug measurement from quantitative and qualitative anti-abatacept antibody research.
Why Abatacept is relevant to biological-drug monitoring research
Abatacept has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Abatacept is a soluble CTLA-4–Ig fusion protein that binds CD80 and CD86 on antigen-presenting cells, reducing CD28-mediated T-cell co-stimulation. Source ↗
Approved Indications
EMA-authorised uses include rheumatoid arthritis, psoriatic arthritis and polyarticular juvenile idiopathic arthritis in defined age and treatment settings. EMA source ↗
Regimen-Specific Exposure
FDA pharmacokinetic data for adult rheumatoid arthritis show measurable steady-state exposure under subcutaneous dosing:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Three verified Abatacept research assays
Ligand-binding ELISA for quantitative analysis of free abatacept in human serum or plasma.
Quantitative ELISA for anti-abatacept antibodies with an assay-specific confirmation workflow.
Qualitative ELISA for reactive or non-reactive assessment of anti-abatacept antibodies using assay-specific cut-off interpretation.
Verified Specifications at a Glance
| Kit | REF | Mode | Analyte | Sample | Volume | Time | Analytical output | Tests | Shelf life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-ABA | ABA-FD-ORE | Quantitative | Free abatacept | Human serum / plasma | 10 µL | 105 min | LOD 3 ng/mL; LOQ 3 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATAB | ABA-QNS-ORE | Quantitative | Anti-abatacept antibodies | Human serum / plasma | 20 µL | 140 min | LOD 50 ng/mL; LOQ 62.5 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATAB | ABA-QLS-ORE | Qualitative | Anti-abatacept antibodies | Human serum / plasma | 20 µL | 140 min | Positive / negative | 96 | 1 year | 2–8°C | 10–30°C |
Analytical specifications are summarised from the current controlled IFUs and exact official product records. Standard curves are official illustrative images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Match the assay to the research question
Abatacept Literature and Product-Use Records
Planning a Abatacept research study?
Matrix Biotek can help identify the appropriate Abatacept assay and prepare regional quotation and delivery information.